The estimated Net Worth of Stuart Mitchell Krassner is at least $671 Thousand dollars as of 24 May 2019. Stuart Krassner owns over 50,000 units of Spectrum Pharmaceuticals stock worth over $116,259 and over the last 20 years Stuart sold SPPI stock worth over $554,565.
Stuart has made over 8 trades of the Spectrum Pharmaceuticals stock since 2012, according to the Form 4 filled with the SEC. Most recently Stuart exercised 50,000 units of SPPI stock worth $304,500 on 24 May 2019.
The largest trade Stuart's ever made was exercising 50,000 units of Spectrum Pharmaceuticals stock on 24 May 2019 worth over $304,500. On average, Stuart trades about 5,424 units every 90 days since 2004. As of 24 May 2019 Stuart still owns at least 112,873 units of Spectrum Pharmaceuticals stock.
You can see the complete history of Stuart Krassner stock trades at the bottom of the page.
Stuart's mailing address filed with the SEC is 157 TECHNOLOGY DRIVE, , IRVINE, CA, 92618.
Over the last 21 years, insiders at Spectrum Pharmaceuticals have traded over $34,101,027 worth of Spectrum Pharmaceuticals stock and bought 60,000 units worth $132,000 . The most active insiders traders include Rajesh C Md Shrotriya, Raymond W Cohen, and Thomas J Riga. On average, Spectrum Pharmaceuticals executives and independent directors trade stock every 26 days with the average trade being worth of $68,584. The most recent stock trade was executed by Nora Brennan on 26 May 2023, trading 32,387 units of SPPI stock currently worth $35,626.
spectrum's core mission is to bring pharmaceutical products to patients for unmet medical needs. to this mission, we bring our years of drug development expertise, coupled with the insight of working in many different oncology indications. spectrum and its subsidiaries have six marketed oncology/hematology products, three for different types of non-hodgkins lymphoma, one for advanced metastatic colorectal cancer, one for a certain type of acute lymphoblastic leukemia (all) and one for multiple myeloma. there are two products in late-stage development, as well as a broad and diversified portfolio of proprietary drugs in various stages of development, all with a focus on oncology and hematology.
Spectrum Pharmaceuticals executives and other stock owners filed with the SEC include: